National Comprehensive Cancer Network



About NCCN

NCCN Updates Multiple Myeloma Guidelines

JENKINTOWN, Pa., January 8, 2007 — The National Comprehensive Cancer Network (NCCN) is pleased to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology™ for Multiple Myeloma. These changes highlight leading developments in the treatment of multiple myeloma and represent the recognized standard for clinical policy in oncology in both the community and the academic practice settings.

Assessing the response to treatment is a key determinant of myeloma treatment. The guidelines list two different sets of response criteria, one developed by the European Group for Bone and Marrow Transplant and the other developed by the International Myeloma Working Group. Both tables are new to the guideline.

Use of the International Staging System (ISS) is also new to the guidelines. Based on the results of the clinical and laboratory evaluation, patients are initially classified as either having smoldering (asymptomatic) disease or active (symptomatic) disease. Those with active disease are then further categorized according to stage, based on either the Durie Salmon staging system or the International Staging System (ISS).

Diagnostic tests such as free light chain, MRI and PET/CT scan have been added to the follow-up/surveillance recommendations throughout the guidelines.

Several new induction regiments for potential transplant candidates are listed in the guidelines. Additional options for non-transplant candidates containing alkylating agents are also listed. Research into various induction regimens has focused on improving the complete response rates in both transplant and non-transplant candidates.

NCCN Clinical Practice Guidelines in Oncology™ are developed and updated through a consensus-driven process with explicit review of the scientific evidence by multidisciplinary panels of expert physicians from NCCN member institutions. The most recent version of this and all the guidelines are available free of charge at www.nccn.org.

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives. For more information, visit NCCN.org.

The NCCN Member Institutions are:

  • Fred & Pamela Buffett Cancer Center
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
  • City of Hope Comprehensive Cancer Center
  • Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center
  • Duke Cancer Institute
  • Fox Chase Cancer Center
  • Huntsman Cancer Institute at the University of Utah
  • Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
  • Mayo Clinic Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • Moffitt Cancer Center
  • The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
  • Roswell Park Cancer Institute
  • Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
  • St. Jude Children's Research Hospital/The University of Tennessee Health Science Center
  • Stanford Cancer Institute
  • University of Alabama at Birmingham Comprehensive Cancer Center
  • UC San Diego Moores Cancer Center
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University of Colorado Cancer Center
  • University of Michigan Comprehensive Cancer Center
  • The University of Texas MD Anderson Cancer Center
  • University of Wisconsin Carbone Cancer Center
  • Vanderbilt-Ingram Cancer Center
  • Yale Cancer Center/Smilow Cancer Hospital